# CellChorus **Source:** https://geo.sig.ai/brands/cellchorus **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** cellchorus.com **Last Updated:** 2026-04-14 ## Summary Houston biotech with visual AI TIMING platform analyzing individual cell behaviors in nanowell grids; $5.78M raised plus NIH STTR grant targeting CAR-T quality release and drug discovery screening. ## Company Overview CellChorus is a Houston-based biotechnology company developing the TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform — a visual AI system that analyzes individual cell behaviors over time in nanoscale grid arrays to characterize how cells interact, move, and function, enabling drug developers and cell therapy manufacturers to optimize their biologics and cell therapies with unprecedented single-cell resolution. Founded in 2021 and backed with $5.78 million in equity funding plus $3.4 million in non-dilutive grants including a $2.5 million NIH STTR Fast-Track grant in partnership with University of Houston, CellChorus serves biotech researchers, cell therapy manufacturers, and pharmaceutical companies. CellChorus' TIMING platform captures time-lapse microscopy data of individual cells (T-cells, NK cells, CAR-T cells) in nanowell grids and applies computer vision AI to analyze cell-to-cell interactions, killing behaviors, and functional characteristics that static endpoint assays miss. For cell therapy developers (CAR-T, NK cell therapies), this means being able to characterize the potency and killing behavior of manufactured immune cells before infusing them in patients — a quality control capability that current release assays cannot provide. For drug discovery, the platform enables screening drug candidates by their effect on individual cell behavior rather than bulk population averages. In 2025, CellChorus competes in the cell analysis, bioprocessing analytics, and drug discovery screening market with Sartorius Incucyte (live cell imaging), BioTek Cytation (multimode imaging), and traditional flow cytometry platforms for cell therapy characterization and drug screening. The cell therapy market (CAR-T, NK cell, TIL therapies) has grown significantly with multiple FDA approvals (Kymriah, Yescarta, Carvykti) driving investment in cell therapy manufacturing quality systems. The NIH grant reflects academic validation of the TIMING platform's scientific approach. The 2025 strategy focuses on cell therapy quality release testing partnerships with CDMOs (contract development and manufacturing organizations), expanding the drug discovery screening use case, and building the regulatory science documentation that supports FDA Quality by Design submissions. ## Frequently Asked Questions ### What is CellChorus? CellChorus is a Houston-based biotechnology company founded in 2021 that specializes in dynamic single-cell analysis. The company uses its proprietary TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform and visual AI to assess individual cell behaviors under various environmental conditions. ### What products and services does CellChorus offer? CellChorus offers the TIMING platform for single-cell analysis, time-lapse imaging microscopy, nanowell grid technology, and visual AI for cell behavior assessment. Additional services include AI-driven immune cell analysis, label-free cell interaction systems, pathogen-immune profiling, and cell therapy manufacturing analytics. ### Who are CellChorus's target customers? CellChorus serves biotech researchers, cell therapy manufacturers, and pharmaceutical companies globally. Their customers require advanced single-cell analysis capabilities for drug development and cell therapy optimization. ### When was CellChorus founded? CellChorus was founded in 2021 and participated in Y Combinator's S21 batch. ### Where is CellChorus located? CellChorus is based in Houston, Texas. The company is affiliated with Houston and partners with the University of Houston. ### How much funding has CellChorus raised? CellChorus has raised $5.78M in total funding and secured $3.4M in non-dilutive grants during 2024-2025. The grants include a $2.5M NIH STTR Fast-Track grant, $350K NIH award, $349.171K NIH award, and $200K BioTools Innovator VANGUARD award. ### What are CellChorus's key achievements? CellChorus has secured multiple prestigious NIH grants totaling $3.4M in non-dilutive funding for 2024-2025, including a $2.5M NIH STTR Fast-Track grant. The company has also established partnerships with University of Houston and NCATS, and was accepted into Y Combinator's S21 batch. ### What technology does CellChorus use? CellChorus employs its proprietary TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform combined with visual AI technology. This approach enables dynamic single-cell characterization and assessment of individual cell behaviors under various environmental conditions. ### What are CellChorus's recent developments? CellChorus received four major grants between May 2024 and August 2025, including a $2.5M NIH STTR Fast-Track grant in October 2024 for work with NCATS and University of Houston. The company also received a $200K BioTools Innovator VANGUARD award in August 2025 for AI-enabled pathogen-immune profiling. ### What is the TIMING platform? TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) is CellChorus's proprietary platform for dynamic single-cell analysis. It uses nanowell grid technology combined with time-lapse imaging and visual AI to study cell behaviors and interactions over time. ## Tags healthtech, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*